NextCure, Inc. (NXTC) is showing up on our radar after ADAR1 Capital Management, LLC, a 10%+ owner of the company, made another open-market purchase of the biotech’s shares. On July 31, 2026, ADAR1 bought 3,300 shares at $4.98 apiece, a purchase worth $16,420.14. Following the trade, ADAR1’s indirectly held stake in NextCure stands at 689,416 shares.
On its own, this is a modest transaction. But it is not standing alone. This filing is one of twelve separate open-market purchases made by ADAR1 Capital Management between July 27 and July 31, 2026. Taken together, those twelve buys add up to $1,611,833 spent acquiring NXTC shares in the span of a single week. That kind of repeated, concentrated buying by the same insider is what we classify as a cluster buy, and it is the real story behind this filing rather than the individual $16,420.14 trade.
Why the Pattern Matters More Than the Single Trade
A single open-market purchase by an insider can reflect any number of personal financial decisions and doesn’t always signal much on its own. A cluster of a dozen purchases over five consecutive trading days from the same entity is a different kind of signal. It suggests a sustained, deliberate allocation of capital into the stock rather than a one-off transaction, and it comes from a holder who already controls more than 10% of the company, giving ADAR1 a large existing stake in NextCure’s outcome.
Academic research on insider trading has found that clustered buying, multiple insiders or repeated purchases by the same insider within a short window, tends to correlate with subsequent stock outperformance more reliably than isolated purchases. That said, this correlation is a historical pattern observed across many companies over long time periods, not a prediction about NextCure specifically, and this article is not suggesting any action be taken based on it.
NextCure is a clinical-stage biopharmaceutical company, and its shares often trade at price levels where relatively small dollar amounts translate into meaningful percentage stakes. ADAR1’s average purchase price across the week’s trades, based on the disclosed transaction, was under $5 per share, consistent with the stock’s current trading range.
The filing reviewed here is publicly available through SEC Form 4 disclosures, which require insiders and major shareholders to report changes in their holdings within two business days of a transaction. Readers interested in the underlying data can review the original filing directly.
→ See all NXTC coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.